Low-molecular-weight heparins in conjunction with thrombolysis for ST-elevation acute myocardial infarction: A critical review of the literature

Cardiology

Volumn 107, Issue 2, 2007, Pages 132-139

  Rubboli, Andrea ^a   Ottani, Filippo ^b   Capecchi, Alessandro ^a   Brancaleoni, Rossella ^a   Galvani, Marcello ^b   Swahn, Ewa ^c  

^a MAGGIORE HOSPITAL   (Italy)

^b MORGAGNI PIERANTONI HOSPITAL   (Italy)

^c LINKÖPING UNIVERSITY   (Sweden)

Author keywords

Acute myocardial infarction; Dalteparin; Enoxaparin; Low molecular weight heparins; Reviparin; Unfractionated heparin

Indexed keywords

ABCIXIMAB; ACETYLSALICYLIC ACID; ALTEPLASE; DALTEPARIN; ENOXAPARIN; FIBRINOLYTIC AGENT; HEPARIN; LOW MOLECULAR WEIGHT HEPARIN; NADROPARIN; PLACEBO; REVIPARIN; STREPTOKINASE; TENECTEPLASE;

ACUTE HEART INFARCTION; BLEEDING; BLEEDING TENDENCY; BLOOD CLOT LYSIS; BRAIN HEMORRHAGE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFECT; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; EVIDENCE BASED PRACTICE; HEART DEATH; HEART REINFARCTION; HEART VENTRICLE THROMBOSIS; HUMAN; MAJOR CLINICAL STUDY; MEDICAL INFORMATION; MEDLINE; PRIORITY JOURNAL; REVIEW; SAMPLE SIZE; ST SEGMENT ELEVATION; STROKE; THERAPY EFFECT; TREATMENT OUTCOME; TREATMENT RESPONSE; UNSTABLE ANGINA PECTORIS; VASCULAR PATENCY;

ANTICOAGULANTS; DALTEPARIN; ENOXAPARIN; FIBRINOLYTIC AGENTS; HEPARIN, LOW-MOLECULAR-WEIGHT; HUMANS; MYOCARDIAL INFARCTION; THROMBOLYTIC THERAPY;

EID: 33847071540     PISSN: 00086312     EISSN: None     Source Type: Journal    
DOI: 10.1159/000094659     Document Type: Review

References (37)

1. Antman EM, Anbe DT, Armstrong PW, et al: ACC/AHA guidelines for the management of patients with ST-elevation myocardial infarction: executive summary and recommendation: a report of the American College of Cardiology/American Heart Association Task Force on practice guidelines. Circulation 2004;110:588-636.
2. Van de Werf F, Ardissino D, Betriu A, et al: Management of acute myocardial infarction in patients presenting with ST-segment elevation. Eur Heart J 2003;24:28-66.
3. The GUSTO Angiographic Investigators: The effects of tissue plasminogen activator, streptokinase, or both on coronary artery patency, ventricular function, and survival after acute myocardial infarction. N Engl J Med 1993;329:1615-1622.
4. Hsia J, Hamilton WP, Kleiman N, et al: A comparison between heparin and low-dose aspirin as adjunctive therapy with tissue plasminogen activator for acute myocardial infarction. N Engl J Med 1990;323:1433-1437.
5. Bleich SD, Nichols TC, Schumacher RB, et al: Effect of heparin on coronary arterial patency after thrombolysis with tissue plasminogen activator in acute myocardial infarction. Am J Cardiol 1990;66:1412-1417.
6. O'Connor CM, Meese R, Carney R, et al: A randomized trial of intravenous heparin in conjunction with anistreplase (anisoylated plasminogen streptokinase activator complex) in acute myocardial infarction: the Duke University Clinical Cardiology Study (DUCCS). J Am Coll Cardiol 1994:23:11-18.
7. De Bono DP, Simoons ML, Tijssen J, et al: Effect of early intravenous heparin on coronary patency, infarct size, and bleeding complications after alteplase thrombolysis: results of a randomized double blind European Cooperative Study Group trial. Br Heart J 1992;67:122-128.
8. The International Study Group: In-hospital mortality and clinical course of 20,891 patients with suspected acute myocardial infarction randomised between alteplase and streptokinase with or without heparin. Lancet 1990;336:71-75.
9. ISIS-3 (Third International Study of Infarct Survival) Collaborative Study Group, ISIS-3: A randomised comparison of streptokinase vs. tissue plasminogen activator vs. anistreplase and of aspirin plus heparin vs. aspirin alone among 41,299 cases of suspected acute myocardial infarction. Lancet 1992;339:753-770.
10. Mahaffey KW, Granger CB, Collins R, et al: Overview of randomized trials of intravenous heparin in patients with acute myocardial infarction treated with thrombolytic therapy. Am J Cardiol 1996;77:551-556.
11. Ridker PM, Herbert PR, Fuster V, Hennekens CH: Are both aspirin and heparin justified as adjuncts to thrombolytic therapy for acute myocardial infarction? Lancet 1993;341:1574-1577.
12. Collins R, Peto R, Baigent C, Sleight P: Aspirin, heparin, and fibrinolytic therapy in suspected acute myocardial infarction. N Engl J Med 1997;336:847-860.
13. Hirsh J, Anand SS, Halperin JL, Fuster V: Guide to anticoagulant therapy: heparin. A statement for healthcare professionals from the American Heart Association. Circulation 2001;103:2994-3018.
14. FRISC Study Group: Low-molecular-weight heparin during instability in coronary artery disease. Lancet 1996;347:561-568.
15. Klein W, Buchwald A, Hillis SE, et al: Comparison of low-molecular-weight heparin with unfractionated heparin acutely and with placebo for 6 weeks in the management of unstable coronary artery disease. Circulation 1997;96:61-68.
16. Cohen M, Demers C, Gurfinkel EP, et al: for the Efficacy and Safety of Subcutaneous Enoxaparin in Non-Q-wave Coronary Events Study Group. A comparison of low-molecular-weight heparin with unfractionated heparin for unstable coronary artery disease. N Engl J Med 1997;337:447-452.
17. Antman EM, McCabe CH, Gurfinkel EP, et al: Enoxaparin prevents death and cardiac ischemic events in unstable angina/non-Q-wave myocardial infarction: results of the Thrombolysis In Myocardial Infarction (TIMI) 11B trial. Circulation 1999;100:1593-1601.
18. FRAX.I.S. Study Group: Comparison of two treatment durations (6 days and 14 days) of a low molecular weight heparin with a 6-day treatment of unfractionated heparin in the initial management of unstable angina or non-Q wave myocardial infartion: FRAX. I.S. (FRAXiparine in Ischemic Syndrome). Eur Heart J 1999;20:1553-1562.
19. Braunwald E, Antman EM, Beasley JW, et al: ACC/AHA 2002 guideline update for the management of patients with unstable angina and non-ST-segment elevation myocardial infarction: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on the management of patients with unstable angina). J Am Coll Cardiol 2002:40:1366-1374.
20. Bertrand ME, Simoons ML, Fox KAA, et al: Management of acute coronary syndromes in patients presenting without persistent ST-segment elevation. Eur Heart J 2002;23:1809-1840.
21. Kontny F, Dale J, Abildgaard U, Pedersen TR: Randomized trial of low molecular weight heparin (Dalteparin) in prevention of left ventricular thrombus formation and arterial embolism after acute anterior myocardial infarction: the Fragmin in Acute Myocardial Infarction (FRAMI) study. J Am Coll Cardiol 1997;30:962-969.
22. Frostfeldt G, Ahlberg G, Gustafsson G, et al: Low molecular weight heparin (Dalteparin) as adjuvant treatment to thrombolysis in acute myocardial infarction - a pilot study: Biochemical Markers in Acute Coronary Syndromes (BIOMACS II). J Am Coll Cardiol 1999;33:627-633.
23. Wallentin L, Bergstrand L, Dellborg M, et al: Low molecular weight heparin (dalteparin) compared to unfractionated heparin as an adjunct to rt-PA (alteplase) for improvement of coronary artery patency in acute myocardial infarction - the ASSENT Plus study. Eur Heart J 2003;24:897-908.
24. Glick A, Kornowski R, Michowich Y, et al: Reduction of reinfarction and angina with use of low-molecular-weight heparin therapy after sterptokinase (and heparin) in acute myocardial infarction. Am J Cardiol 1996;77:1145-1148.
25. Ross AM, Molhoek P, Lundergan C, et al: Randomized comparison of enoxaparin, a low-molecular-weight heparin, with unfractioned heparin adjunctive to recombinant tissue plasminogen activator thrombolysis and aspirin. Second trial of Heparin and Aspirin Reperfusion Therapy (HART-II). Circulation 2001;104:648-652.
26. The Assessment of the Safety and Efficacy of a New Thrombolytic regimen (ASSENT)-3 investigators: Efficacy and safety of tenecteplase in combination with enoxaparin, abciximab, or unfractioned heparin: the ASSENT-3 randomised trial in acute myocardial infarction. Lancet 2001;358:605-613.
27. Antman EM, Louwerenburg HW, Baars HF, et al: Enoxaparin as adjunctive antithrombin therapy for ST-elevation myocardial infarction. Results of the ENTIRE-Thrombolysis In Myocardial Infarction (TIMI) 23 Trial. Circulation 2002;105:1642-1649.
28. Baird SH, Menown IBA, McBride SJ, et al: Randomized comparison of enoxaparin with unfractioned heparin following fibrinolytic therapy for acute myocardial infarction. Eur Heart J 2002;23:627-632.
29. Simoons ML, Krzeminska-Pakula M, Alonso A, et al: Improved reperfusion and clinical outcome with enoxaparin as an adjunct to streptokinase thrombolysis in acute myocardial infarction. The AMI-SK Study. Eur Heart J 2002;23:1282-1290.
30. Wallentin L, Goldstein P, Armstrong PW, et al: Efficacy and safety of tenecteplase in combination with the low-molecular-weight heparin enoxaparin or unfractionated heparin in the prehospital setting. The Assessment of the Safety and Efficacy of a New Thrombolytic Regimen (ASSENT)-3 PLUS randomized trial in acute myocardial infarction. Circulation 2003;108:135-142.
31. Tatu-Chitoiu G, Teodorescu C, Capraru P, et al: Accelerated streptokinase and enoxaparin in ST-segment elevation acute myocardial infarction (the ASENOX study). Pol Heart J 2004;60:441-446.
32. The CREATE Trial Group Investigators: Effects of reviparin, a low-molecular-weight heparin, on mortality, reinfarction, and strokes in patients with acute myocardial infarction presenting with ST-segment elevation. JAMA 2005;293:427-435.
33. Collignon F, Frydman A, Caplain H, et al: Comparison of the pharmacokinetic profiles of three low molecular weight mass heparins - dalteparin, enoxaparin and nadroparin - administered subcutaneously in healthy volunteers (doses for prevention of thromboembolism). Thromb Haemost 1995;73:630-640.
34. Montalescot G, Collet JP, Lison L, et al: Effects of various anticoagulant treatments on von Willebrand factor release in unstable angina. J Am Coll Cardiol 2000;36:110-114.
35. Sabatine MS, Morrow DA, Montalescot G, et al: Angiographic and clinical outcomes in patients receiving low-molecular-weight heparin versus unfractionated heparin in ST-elevation myocardial infarction treated with fibrinolytics in the CLARITY-TIMI 28 trial. Circulation 2005;112:3846-3854.
36. Dubois CL, Belmans A, Granger CB, et al: Outcome of urgent and elective percutaneous coronary interventions after pharmacologic reperfusion with tenecteplase combined with unfractionated heparin, enoxaparin or abciximab. J Am Coll Cardiol 2003;42:1178-1185.
37. Mark DB, Cowper PA, Berkowitz SD, et al: Economic assessment of low-molecular-weight heparin (enoxaparin) versus unfractioned heparin in acute coronary syndrome patients: results from the ESSENCE randomized trial. Efficacy and Safety of Subcutaneous Enoxaparin in Non-Q-wave Coronary Events (unstable angina angina or non-Q-wave myocardial infarction). Circulation 1998;97:1702-1707.